Logotype for Aethlon Medical Inc

Aethlon Medical (AEMD) Q2 2027 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Aethlon Medical Inc

Q2 2027 earnings summary

12 Nov, 2026

Executive summary

  • Signed a two-step merger agreement with North Immunology on September 17, 2026; the combined business is expected to operate as North Immunology, with closing expected in Q1 2027 subject to conditions.

  • The proposed merger would shift the combined business to North Immunology’s pipeline and may wind down legacy Hemopurifier activities; workforce reductions began near quarter-end, with retained staff supporting compliance and the Australian trial.

  • A proposed contingent value right could provide proceeds from monetizing the legacy Hemopurifier business, but payment is not assured.

Financial highlights

  • Q2 operating expenses were $2.675M, up 77.2% from $1.510M; net loss was $2.618M versus $1.487M, driven chiefly by merger-related professional fees and no current-period Australian R&D tax incentive.

  • H1 operating expenses were $4.254M versus $3.302M, and net loss was $4.165M versus $3.249M.

  • Cash and cash equivalents were $6.487M at September 30, 2026, versus $5.026M at March 31, 2026; H1 operating cash use was $3.633M.

Outlook and guidance

  • Existing cash resources are expected to fund the reduced operating plan for at least 12 months from financial-statement issuance, including if the merger does not close; the plan includes completing the Australian trial.

  • If the merger closes, anticipated financing and the combined operating plan are expected to support at least 12 months of operations after closing; closing is expected in Q1 2027, subject to conditions.

  • Eight patients have been treated across three cohorts; recruitment of one additional patient is intended to conclude in connection with the proposed merger, followed by analysis of available data.

  • Additional capital would be required to resume or expand Hemopurifier development; roughly $500,000 of ATM capacity remained, subject to market and stock-price conditions.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Aethlon Medical